We are doing this study to find out if an experimental drug called LY4337713 (the study drug) is a safe and effective option for people who have FAP-positive solid tumors. The study drug is a type of radiotherapy that is intended to target and attach only to FAP. The goal of targeted radiotherapy is to provide selective delivery of radiation doses that can destroy tumor cells.

Cancers with Fibroblast Activation Protein (FAP) Positive Solid Tumors

Adults ages 18+ who:

• Are diagnosed with one of the following forms of cancer with a solid tumor present: adenocarcinoma of the pancreas, HR-positive & HER2-negative breast cancer, HER2-positive breast cancer, triple-negative breast cancer, platinum-resistant or refractory ovarian cancer, gastric adenocarcinoma, colorectal cancer, squamous cell carcinoma or adenocarcinoma esophageal cancer, or cholangiocarcinoma
• Have clinical or imaging evidence of FAP expression

For more information, contact the study team at dana.a.warren@duke.edu.

If you choose to join this study, you will:

• Get an intravenous (IV) injection of the study drug either every 4 weeks or every 6 weeks, depending on when you are enrolled
• Have blood draws and give urine samples
• Have regular CT or MRI scans